Hetero Ring Patents (Class 544/212)
  • Patent number: 10377747
    Abstract: The present disclosure relates to 2-arylamino pyridine, pyrimidine, or triazine derivatives, and the preparation method and use thereof. The 2-arylamino pyridine, pyrimidine, or triazine derivatives may act on certain mutated forms of epidermal growth factor receptor, for example the L858R activating mutant, the delE746_A750 mutant, the Exonl9 deletion activating mutant, and the T790M resistance mutant, so as to be used for treatment and prevention of diseases and medical conditions. The 2-arylamino pyridine, pyrimidine, or triazine derivatives may be used for treatment and prevention of cancer. The present disclosure also relates to a pharmaceutical composition comprising 2-arylamino pyridine, pyrimidine, or triazine derivatives, intermediates useful in the manufacture of 2-arylamino pyridine, pyrimidine, or triazine derivatives, and to methods of treatment of diseases mediated by various different forms of EGFR using 2-arylamino pyridine, pyrimidine, or triazine derivatives.
    Type: Grant
    Filed: August 31, 2015
    Date of Patent: August 13, 2019
    Assignee: Wuxi Shuangliang Biotechnology Co., Ltd.
    Inventors: Jiaquan Wu, Haijun Zhang, Huanyan Cao, Shenshuang Jin, Shuai Zhang, Zhenghua Lu, Jian Dong, Chengchen Wang, Qiu Tan
  • Patent number: 10230057
    Abstract: Provided are an organic electroluminescence device having high current efficiency and a long lifetime, and a biscarbazole derivative for realizing the device. The biscarbazole derivative has a specific substituent. The organic EL device has a plurality of organic thin-film layers including a light emitting layer between a cathode and an anode, and at least one layer of the organic thin-film layers contains the biscarbazole derivative.
    Type: Grant
    Filed: October 9, 2017
    Date of Patent: March 12, 2019
    Assignee: IDEMITSU KOSAN CO., LTD.
    Inventors: Tetsuya Inoue, Mitsunori Ito, Tomoki Kato, Kumiko Gorai, Kazuki Nishimura, Takayasu Sado
  • Patent number: 10084142
    Abstract: An organic electroluminescent device includes: a substrate; a first electrode on the substrate; a second electrode on the first electrode; and a plurality of lamination layers between the first and second electrodes; wherein at least one of the plurality of lamination layers includes a carbazole compound represented by Formula 1: The carbazole compound may improve the emission efficiency of the organic electroluminescent device.
    Type: Grant
    Filed: December 11, 2015
    Date of Patent: September 25, 2018
    Assignee: Samsung Display Co., Ltd.
    Inventors: Junta Fuchiwaki, Hiroaki Itoi
  • Patent number: 9985217
    Abstract: A material for an organic electroluminescent device and an organic electroluminescent device including the same, according to one or more embodiments of the present disclosure, include an amine derivative represented by Formula 1. When the amine derivative represented by Formula 1 is included in the emission layer, the emission efficiency of the organic electroluminescent device may be improved.
    Type: Grant
    Filed: December 28, 2015
    Date of Patent: May 29, 2018
    Assignee: Samsung Display Co., Ltd.
    Inventors: Masatsugu Ueno, Junta Fuchiwaki
  • Patent number: 9655902
    Abstract: Compounds of Formula I, including pharmaceutically acceptable salts thereof, are set forth, in addition to compositions and methods of using these compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.
    Type: Grant
    Filed: January 23, 2014
    Date of Patent: May 23, 2017
    Assignee: Bristol-Myers Squibb Company
    Inventors: Tao Wang, Zhongxing Zhang, Ying Han, Zhiwei Yin, Paul Michael Scola
  • Patent number: 9596753
    Abstract: An ultra low loss dielectric thermosetting resin composition has at least one cyanate ester component (A) and at least one reactive intermediate component (B) that is capable of copolymerization with said component (A). The invention is a cyanate ester resin of the form: Tn-[W-(Z)f/(H)1?f-W]n?1-[W-(Z)f/(H)1?f-(OCN)f/(R)1?f]n+2, wherein T is a 1,3,5-substituted-triazine moiety (C3N3); W is a linking atom between triazine and either component A or component B; Z is component (A); H is component (B); OCN is a cyanate ester end group; R is a reactive end group of component B; n is an integer greater than or equal to 1; and f is a weight or mole fraction of component A. The composition exhibits excellent dielectric properties and yields a high performance laminate for use in high layer count, multilayer printed circuit board (PCB), prepregs, resin coated copper (RCC), film adhesives, high frequency radomes, radio frequency (RF) laminates and various composites.
    Type: Grant
    Filed: August 18, 2016
    Date of Patent: March 14, 2017
    Assignee: NOVOSET, LLC
    Inventors: Sajal Das, Patrick Shipman
  • Patent number: 9439284
    Abstract: A ultra low loss dielectric thermosetting resin composition has at least one cyanate ester component (A) and at least one reactive intermediate component (B) that is capable of copolymerization with said component (A). The invention is a cyanate ester resin of the form: Tn-[W-(Z)f/(H)1?f-W]n?1-[W-(Z)f/(H)1?f-(OCN)f/(R)1?f]n+2, wherein T is a 1,3,5-substituted-triazine moiety (C3N3); W is a linking atom between triazine and either component A or component B; Z is component (A); H is component (B); OCN is a cyanate ester end group; R is a reactive end group of component B; n is an integer greater than or equal to 1; and f is a weight or mole fraction of component A. The composition exhibits excellent dielectric properties and yields a high performance laminate for use in high layer count, multilayer printed circuit board (PCB), prepregs, resin coated copper (RCC), film adhesives, high frequency radomes, radio frequency (RF) laminates and various composites.
    Type: Grant
    Filed: May 2, 2016
    Date of Patent: September 6, 2016
    Assignee: Novoset LLC
    Inventors: Sajal Das, Patrick Shipman
  • Patent number: 9422311
    Abstract: The disclosure provides compounds of formula I, including pharmaceutically acceptable salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.
    Type: Grant
    Filed: October 15, 2013
    Date of Patent: August 23, 2016
    Assignee: Bristol-Myers Squibb Company
    Inventors: Tao Wang, Zhongxing Zhang, Eric P. Gillis, Paul Michael Scola
  • Patent number: 9332637
    Abstract: A ultra low loss dielectric thermosetting resin composition has at least one cyanate ester component (A) and at least one reactive intermediate component (B) that is capable of copolymerization with said component (A). The invention is a cyanate ester resin of the form: Tn-[W-(Z)f/(H)1?f-W]n?1-[W-(Z)f/(H)1?f-(OCN)f/(R)1?f]n+2, wherein T is a 1,3,5-substituted-triazine moiety (C3N3); W is a linking atom between triazine and either component A or component B; Z is component (A); H is component (B); OCN is a cyanate ester end group; R is a reactive end group of component B; n is an integer greater than or equal to 1; and f is a weight or mole fraction of component A. The composition exhibits excellent dielectric properties and yields a high performance laminate for use in high layer count, multilayer printed circuit board (PCB), prepregs, resin coated copper (RCC), film adhesives, high frequency radomes, radio frequency (RF) laminates and various composites.
    Type: Grant
    Filed: November 4, 2013
    Date of Patent: May 3, 2016
    Assignee: Novoset LLC
    Inventors: Sajal Das, Patrick Shipman
  • Patent number: 9120790
    Abstract: The present invention relates to compounds useful as inhibitors of protein kinases, particularly of JAK family kinases. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.
    Type: Grant
    Filed: July 24, 2014
    Date of Patent: September 1, 2015
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Luc Farmer, Gabriel Martinez-Botella, Albert Pierce, Francesco Salituro, Jian Wang, Marion W. Wannamaker, Tiansheng Wang
  • Publication number: 20150144937
    Abstract: Provided are a compound represented by the following Chemical Formula 1 for an organic optoelectronic device, an organic light emitting diode including the same, and a display device including the organic light emitting diode. The structure of Chemical Formula 1 is described in the specification. The compound for the organic photoelectric device provides an organic light emitting diode having excellent life-span characteristics due to excellent electrochemical and thermal stability and high luminous efficiency at a low driving voltage.
    Type: Application
    Filed: February 3, 2015
    Publication date: May 28, 2015
    Inventors: Moo-Jin PARK, Eun-Sun YU, Mi-Young CHAE, Byung-Ku KIM, Hyo-Ju SEO, Jae-Deuk YANG
  • Publication number: 20150126506
    Abstract: Compounds and pharmaceutical compositions that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including PI3 kinase activity, are described herein.
    Type: Application
    Filed: January 8, 2015
    Publication date: May 7, 2015
    Inventors: Alfredo C. CASTRO, Catherine A. EVANS, Somarajannair JANARDANANNAIR, Andre LESCARBEAU, Tao LIU, Daniel A. SNYDER, Martin R. TREMBLAY, Pingda REN, Yi LIU, Liansheng LI, Katrina CHAN
  • Publication number: 20150126736
    Abstract: The present invention relates to a novel organic electroluminescent compound and an organic electroluminescent device comprising the same. The organic electroluminescent compound according to the present invention has excellent luminous efficiency, power efficiency, and lifespan characteristic. Using the compounds of the present invention, it is possible to manufacture an OLED device with a long operating lifespan. In addition, the compounds can improve the power efficiency of the device to reduce overall power consumption.
    Type: Application
    Filed: May 2, 2013
    Publication date: May 7, 2015
    Inventors: Young-Jun Cho, Ji-Song Jun, Hee-Ryong Kang, Bong-Ok Kim, Hyuck-Joo Kwon, Kyung-Joo Lee, Seon-Woo Lee, Hong-Yeop Na, Hyo-Nim Shin, Jeong-eun Yang, Soo-Jin Yang
  • Publication number: 20150119362
    Abstract: The present invention relates to compounds and methods useful as inhibitors of phosphodiesterase 4 (PDE4) for the treatment or prevention of disease.
    Type: Application
    Filed: October 24, 2013
    Publication date: April 30, 2015
    Inventors: Mark E. Gurney, Timothy J. Hagen, Joel R. Walker, Xuesheng Mo, A. Samuel Vellekoop, Robert Campbell, Lei Zhu, Donna L. Romero
  • Patent number: 9017827
    Abstract: A compound for an organic optoelectronic device, an organic light emitting diode, and a display device, the compound including sequentially combined substituents represented by the following Chemical Formulae 1 to 3:
    Type: Grant
    Filed: December 23, 2011
    Date of Patent: April 28, 2015
    Assignee: Cheil Industries, Inc.
    Inventors: Sung-Hyun Jung, Hyung-Sun Kim, Ho-Jae Lee, Eun-Sun Yu, Mi-Young Chae, Ja-Hyun Kim
  • Publication number: 20150111871
    Abstract: The present invention relates to compounds useful as inhibitors of DNA-PK. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.
    Type: Application
    Filed: October 16, 2014
    Publication date: April 23, 2015
    Applicant: VERTEX PHARMACEUTICALS INCORPORATED
    Inventors: Paul S. Charifson, Kevin Michael Cottrell, Hongbo Deng, John P. Duffy, Huai Gao, Simon Giroux, Jeremy Green, Katrina Lee Jackson, Joseph M. Kennedy, David J. Lauffer, Mark Willem Ledeboer, Pan Li, John Patrick Maxwell, Mark A. Morris, Albert Charles Pierce, Nathan D. Waal, Jinwang Xu
  • Publication number: 20150111873
    Abstract: Pyrazolo[1,5-a][1,3,5]triazine derivatives and/or pharmaceutically acceptable salts thereof, the use of these derivatives as pharmaceutically active agents, especially for the prophylaxis and/or treatment of infectious diseases, including opportunistic diseases, immunological diseases, autoimmune diseases, cardiovascular diseases, cell proliferative diseases, inflammation, erectile dysfunction and stroke, and pharmaceutical compositions containing at least one of said pyrazolo[1,5-a][1,3,5]triazine derivatives and/or pharmaceutically acceptable salts thereof. Furthermore, the present invention relates to the use of said pyrazolo[1,5-a][1,3,5]triazine derivatives as inhibitors for a protein kinase.
    Type: Application
    Filed: March 1, 2013
    Publication date: April 23, 2015
    Applicant: LEAD DISCOVERY CENTER GMBH
    Inventors: Jan Eickhoff, Gunther Zischinsky, Uwe Koch, Gerd Rühter, Carsten Schultz-Fademrecht, Peter Nussbaumer
  • Publication number: 20150090965
    Abstract: A compound represented by Formula 1 or 2, and an organic light-emitting device including the same are disclosed. Formulae 1 and 2 are defined as in the specification.
    Type: Application
    Filed: April 2, 2014
    Publication date: April 2, 2015
    Applicant: Samsung Display Co., Ltd.
    Inventors: Jun-Ha Park, Mi-Eun Jun, Eun-Jae Jeong
  • Publication number: 20150090968
    Abstract: A condensed cyclic compound represented by Formula 1: wherein in Formula 1, Groups X1 to X3, L11, L12, R11, and R12, and variables a11, a12, b11, b12, c11, and c12 are described in the specification.
    Type: Application
    Filed: June 2, 2014
    Publication date: April 2, 2015
    Applicants: Samsung Electronics Co., Ltd., CHEIL INDUSTRIES INC.
    Inventors: Chang-woo KIM, O-hyun KWON, Sang-dong KIM, Kyu-young HWANG, Byoung-ki CHOI
  • Publication number: 20150090963
    Abstract: An organic compound represented by Formula 1 is disclosed. An organic light-emitting device including the organic compound is also disclosed.
    Type: Application
    Filed: February 25, 2014
    Publication date: April 2, 2015
    Applicant: SAMSUNG DISPLAY CO., LTD.
    Inventors: Young-Kook Kim, Kwang-Hyun Kim, Eun-Young Lee
  • Patent number: 8993757
    Abstract: The invention relates to a N-piperidin-4-yl derivative having the general Formula I or a pharmaceutically acceptable salt thereof, to pharmaceutical compositions comprising the same and to the use of said N-piperidin-4-yl derivatives for the treatment and prevention of endometriosis, for the treatment and prevention of pre-menopausal and peri-menopausal hormone-dependent breast cancer, for contraception, or for the treatment of uterine fibroids or other menstrual-related disorders.
    Type: Grant
    Filed: September 14, 2012
    Date of Patent: March 31, 2015
    Assignee: Merck Sharp & Dohme B.V.
    Inventors: Ines Huisman, Marcelis Van Der Stelt, Wouter Wiedenhof, Charles Anthony Graham Baker-Glenn, Wesley Peter Blackaby, Naimisha Trivedi
  • Publication number: 20150069368
    Abstract: A compound for an organic photoelectric device, the compound being represented by the following Chemical Formula (“CF”) 1:
    Type: Application
    Filed: October 20, 2014
    Publication date: March 12, 2015
    Inventors: Hyung-Sun KIM, Eun-Sun YU, Young-Hoon KIM, Soo-Hyun MIN, Ho-Jae LEE, Eui-Su KANG, Mi-Young CHAE
  • Publication number: 20150060788
    Abstract: A compound for an organic optoelectric device, an organic optoelectric device including the same, and a display device including the organic optoelectric device, the compound including a combination of a moiety represented by the following Chemical Formula I and a moiety represented by the following Chemical Formula II:
    Type: Application
    Filed: May 21, 2014
    Publication date: March 5, 2015
    Inventors: Dong-Kyu RYU, Jin-Seok HONG, Eun-Sun YU, Dong-Min KANG, Sang-Shin LEE, Han-Ill LEE, Yu-Na JANG, Soo-Young JEONG, Su-Jin HAN
  • Publication number: 20150057445
    Abstract: The present invention relates to substances, to electroluminescent device comprising these substances, and to the use thereof.
    Type: Application
    Filed: October 30, 2014
    Publication date: February 26, 2015
    Inventors: Rémi Mamouk Anémian, Aurélie Ludemann, Thomas Eberle, Sigurd Hoeger, Eva M. REIS, Vanessa Bobbe
  • Patent number: 8962158
    Abstract: Provided is an organic electroluminescent device (organic EL device), which has improved luminous efficiency, has sufficient driving stability, and has a simple construction. The organic EL device of the present invention is an organic electroluminescent device, including a light-emitting layer and a hole-transporting layer between an anode and a cathode laminated on a substrate, in which the light-emitting layer contains a phosphorescent light-emitting dopant and an indolocarbazole compound that serves as a host material, or alternatively, the hole-transporting layer contains an indolocarbazole compound. The indolocarbazole compound is represented by the following formula (1). In the formula: A1's each represent an aromatic hydrocarbon group or an aromatic heterocyclic group, provided that at least one of A1's has a fused ring structure; and R1's each represent a hydrogen atom, an alkyl group, an alkoxy group, or an acyl group.
    Type: Grant
    Filed: March 25, 2010
    Date of Patent: February 24, 2015
    Assignee: Nippon Steel & Sumikin Chemical Co., Ltd.
    Inventors: Masaki Komori, Takahiro Kai, Toshihiro Yamamoto
  • Patent number: 8952150
    Abstract: Disclosed are compounds for inhibiting prostaglandin transporter (PGT) activity, pharmaceuticals compositions including the compounds, and methods of treating subjects using the compounds.
    Type: Grant
    Filed: September 20, 2010
    Date of Patent: February 10, 2015
    Assignee: Albert Einstein College of Medicine of Yeshiva University
    Inventors: Victor L. Schuster, Yuling Chi, Andrew S. Wasmuth, Richard S. Pottorf, Gary L. Olson
  • Publication number: 20150034914
    Abstract: An organic compound represented by a combination of a moiety represented by the following Chemical Formula 1, a moiety represented by the following Chemical Formula 2, and a moiety represented by the following Chemical Formula 3,
    Type: Application
    Filed: March 5, 2014
    Publication date: February 5, 2015
    Inventors: Han-Ill LEE, Dong-Kyu RYU, Eun-Sun YU, Jin-Seok HONG, Dong-Min KANG, Ji-Hun SHIN, Sang-Shin LEE, Yu-Na JANG, Soo-Young JEONG, Su-Jin HAN
  • Publication number: 20150031652
    Abstract: Disclosed are compounds of the following formula: in which R1, R2, R3, R4, R5, R6, R7, X, and t are defined in the specification. Also disclosed are pharmaceutical compositions, kits, and articles of manufacture, which contain the compounds, methods and intermediates useful for making the compounds, and methods of using the compounds to treat diseases, disorders, and conditions related to PARP activity.
    Type: Application
    Filed: August 1, 2014
    Publication date: January 29, 2015
    Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Anthony R. Gangloff, Andrew John Jennings, Benjamin Jones, Andre A. Kiryanov
  • Patent number: 8937176
    Abstract: This invention relates to compounds of formula I their use as positive allosteric modulators of mGlu5 receptor activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of neurological and psychiatric disorders associated with glutamate dysfunction such as schizophrenia or cognitive decline such as dementia or cognitive impairment. A, B, Ar, R1, R2, R3 have meanings given in the description.
    Type: Grant
    Filed: December 10, 2012
    Date of Patent: January 20, 2015
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Klaus Rudolf, Daniel Bischoff, Georg Dahmann, Matthias Grauert, Raimund Kuelzer
  • Publication number: 20150018329
    Abstract: The present invention relates to pyrazolo[1,5-a][1,3,5]triazine derivatives and/or pharmaceutically acceptable salts thereof, the use of these derivatives as pharmaceutically active agents, especially for the prophylaxis and/or treatment of infectious diseases, including opportunistic diseases, immunological diseases, autoimmune diseases, cardiovascular diseases, cell proliferative diseases, inflammation, erectile dysfunction and stroke, and pharmaceutical compositions containing at least one of said pyrazolo[1,5-a][1,3,5]triazine derivatives and/or pharmaceutically acceptable salts thereof. Furthermore, the present invention relates to the use of said pyrazolo[1,5-a][1,3,5]triazine derivatives as inhibitors for a protein kinase.
    Type: Application
    Filed: March 1, 2013
    Publication date: January 15, 2015
    Applicant: LEAD DISCOVERY CENTER GMBH
    Inventors: Jan Eickhoff, Gunther Zischinsky, Uwe Koch
  • Publication number: 20150011751
    Abstract: To provide a novel triazine derivative represented by the following formula (I): A triazine derivative represented by the following formula (I): wherein R1 represents a substituted or unsubstituted aryl group, a substituted or unsubstituted heterocyclic ring, a substituted or unsubstituted heterocyclic fused ring, or a substituted or unsubstituted alkynyl group, R2 represents a hydrogen atom, a halogen atom, a substituted or unsubstituted lower alkyl group, or a substituted or unsubstituted alkoxy group, R3 represents a substituted or unsubstituted aryl group, a substituted or unsubstituted heterocyclic ring, or a substituted or unsubstituted heterocyclic fused ring, R4 represents a hydrogen atom, a substituted or unsubstituted lower alkyl group, a substituted or unsubstituted alkoxy group, a substituted or unsubstituted amino group, or a halogen atom, and R5 represents a hydrogen atom, a substituted or unsubstituted lower alkyl group, or R1 and R5 may be combined to form a saturated or unsaturate
    Type: Application
    Filed: March 7, 2013
    Publication date: January 8, 2015
    Inventors: Wataru Kawahata, Tokiko Asami, Masaaki Sawa, Yuko Asamitsu, Takayuki Irie, Takahiro Miyake, Takao Kiyoi
  • Publication number: 20150008423
    Abstract: A biscarbazole derivative of the invention is represented by a formula (1) below. In the formula (1): A1 represents a substituted or unsubstituted nitrogen-containing heterocyclic group having 1 to 30 ring carbon atoms; A2 represents a substituted or unsubstituted aromatic hydrocarbon group having 6 to 30 ring carbon atoms, or substituted or unsubstituted nitrogen-containing heterocyclic group having 1 to 30 ring carbon atoms; X1 and X2 each are a linking group; Y1 to Y4 each represent a substituent; p and q represent an integer of 1 to 4; and r and s represent an integer of 1 to 3.
    Type: Application
    Filed: September 22, 2014
    Publication date: January 8, 2015
    Applicant: IDEMITSU KOSAN CO., LTD.
    Inventors: Tetsuya INOUE, Mitsunori ITO, Kei YOSHIDA, Kumiko HIBINO, Kazuki NISHIMURA, Toshinari OGIWARA, Kiyoshi IKEDA
  • Publication number: 20150001471
    Abstract: The present disclosure generally relates to novel compounds containing carbazole and triazine with different number of phenyl units attached to its core. In particular, the disclosure relates to compositions and/or devices comprising these compounds as hosts for PHOLEDs.
    Type: Application
    Filed: June 28, 2013
    Publication date: January 1, 2015
    Inventors: Pierre-Luc T. Boudreault, Alexey Dyatkin, Chuanjun Xia, Hitoshi Yamamoto
  • Patent number: 8921547
    Abstract: The present invention provides compounds which are modulators of TNF-? signaling and methods of use thereof for treating a patient having a TNF-? mediated condition.
    Type: Grant
    Filed: July 19, 2013
    Date of Patent: December 30, 2014
    Assignee: Genzyme Corporation
    Inventors: Scott F. Sneddon, John L. Kane, Bradford H. Hirth, Frederic Vinick, Shuang Qiao, Sharon R. Nahill, John M. Williams, Hans-Peter Biemann
  • Publication number: 20140374724
    Abstract: The present invention relates to a novel indole-based compound having superior hole injection and transport capabilities, light-emitting capabilities, and the like, and an organic electroluminescent device which comprises the indole-based compound in one or more organic layers thereof so as to thereby achieve improved characteristics, such as light-emitting efficiency, driving voltage, and lifespan characteristics.
    Type: Application
    Filed: December 7, 2012
    Publication date: December 25, 2014
    Applicant: DOOSAN CORPORATION
    Inventors: Hoe Moon Kim, Sung Moo Kim, Young Bae Kim, Tae Hyung Kim, Ho Cheol Park, Chang Jun Lee, Young Mi Baek, Jin Yong Shin
  • Publication number: 20140374706
    Abstract: Disclosed are a compound for an organic optoelectric device, an organic optoelectric device including the same and a display device including the organic optoelectric device, wherein the compound for an organic optoelectric device is represented by the following Chemical Formula 1, In the above Chemical Formula 1, R1 to R7, X, L1 and L2 are the same as described in the detailed description.
    Type: Application
    Filed: November 20, 2013
    Publication date: December 25, 2014
    Inventors: Jin-Seok HONG, Dong-Min KANG, Eun-Sun YU, Soo-Young JEONG, Ji-Hun SHIN, Dong-Kyu RYU, Han-ill LEE, Yu-Na JANG
  • Patent number: 8916702
    Abstract: The disclosure provides compounds of formula I, including pharmaceutically acceptable salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.
    Type: Grant
    Filed: February 4, 2013
    Date of Patent: December 23, 2014
    Assignee: Bristol-Myers Squibb Company
    Inventors: Tao Wang, Paul Michael Scola, Zhongxing Zhang, Zhiwei Yin, Qian Zhao
  • Patent number: 8916557
    Abstract: The present invention relates to substituted 4-Aryl-N-phenyl-1,3,5-triazin-2-amines of general formula (I) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular of hyper-proliferative disorders and/or virally induced infectious diseases and/or of cardiovascular diseases. The invention further relates to intermediate compounds useful in the preparation of said compounds of general formula (I).
    Type: Grant
    Filed: April 18, 2012
    Date of Patent: December 23, 2014
    Assignee: Bayer Intellectual Property GmbH
    Inventors: Ulrich Lücking, Rolf Bohlmann, Arne Scholz, Gerhard Siemeister, Mark Jean Gnoth, Ulf Bömer, Gerd Rühter, Carsten Schultz-Fademrecht, Dirk Kosemund, Philip Lienau
  • Publication number: 20140367667
    Abstract: A compound represented by the following formula (1):
    Type: Application
    Filed: December 28, 2012
    Publication date: December 18, 2014
    Applicant: Idemitsu Kosan Co., Ltd.
    Inventors: Toshihiro Iwakuma, Kazuki Nishimura
  • Publication number: 20140361267
    Abstract: Provided is a heterocyclic compound represented by Formula 1 below and an organic light-emitting device including the same. In Formula 1, R1 to R8 are each independently a hydrogen atom, a deuterium atom, a substituted or unsubstituted C1 to C60 alkyl group, a substituted or unsubstituted C3 to C60 cycloalkyl group, a substituted or unsubstituted C2 to C60 heteroaryl group, a substituted or unsubstituted C6 to C60 aryl group, or a substituted or unsubstituted C6 to C60 condensed polycyclic group, with the proviso that R2 is not wherein X is O, S, or Se.
    Type: Application
    Filed: April 11, 2014
    Publication date: December 11, 2014
    Applicant: SAMSUNG DISPLAY CO., LTD.
    Inventors: Soo-Yon KIM, Seok-Hwan HWANG, Young-Kook KIM, Jun-Ha PARK, Hye-Jin JUNG, Eun-Young LEE, Sang-Hyun HAN, Jin-O LIM, Eun-Jae JEONG, Jong-Hyuk LEE
  • Publication number: 20140361254
    Abstract: A heterocyclic compound represented by Formula 1 below and an organic light-emitting device including the heterocyclic compound are provided: Ar1, Ar2, Ar3 and X in Formula 1 are defined as in the specification.
    Type: Application
    Filed: September 26, 2013
    Publication date: December 11, 2014
    Applicant: SAMSUNG DISPLAY CO., LTD.
    Inventors: Seok-Hwan Hwang, Young-Kook Kim, Hye-Jin Jung, Jun-Ha Park, Eun-Young Lee, Jin-O Lim, Sang-Hyun Han, Eun-Jae Jeong, Soo-Yon Kim, Jong-Hyuk Lee
  • Publication number: 20140353640
    Abstract: A heterocyclic compound wherein three five-membered rings are fused to one benzene ring and a saturated or unsaturated ring is fused to each five-membered ring. An organic electroluminescence device includes one or more organic thin film layers between an anode and a cathode. The one or more organic thin film layers include a light emitting layer. At least one layer of the one or more organic thin film layers includes the heterocyclic compound.
    Type: Application
    Filed: May 29, 2014
    Publication date: December 4, 2014
    Applicant: Idemitsu Kosan Co., Ltd.
    Inventors: Tasuku HAKETA, Masahiro KAWAMURA, Kazuki NISHIMURA, Yumiko MIZUKI, Hirokatsu ITO, Tomoharu HAYAMA
  • Publication number: 20140349998
    Abstract: The instant invention provides compounds of formula I which are JAK3 inhibitors. Specifically, the compounds of formula I are pyrrolo[2,3-d]pyrimidine derivative compounds. The instant invention also provides methods of treating JAK-mediated diseases such as rheumatoid arthritis, asthma, COPD and cancer, by administering the pyrrolo[2,3-d]pyrimidine-derivative compounds of formula I.
    Type: Application
    Filed: November 30, 2012
    Publication date: November 27, 2014
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Sean P Ahearn, Matthew Christopher, Christopher Dinsmore, Joon Jung, Qinglin Pu, Alexey Rivkin, Mark E. Scott, David J. Witter, Hyun Chong Woo, Brandon Cash
  • Publication number: 20140346483
    Abstract: Disclosed are a compound for an organic optoelectronic device, an organic light emitting diode including the same, and a display device including the organic light emitting diode. The compound for an organic optoelectronic device represented by a combination of the following Chemical Formula 1; and Chemical Formula 2 or 3 provides an organic light emitting diode having life-span characteristics due to excellent electrochemical and thermal stability, and high luminous efficiency at a low driving voltage.
    Type: Application
    Filed: September 25, 2012
    Publication date: November 27, 2014
    Inventors: Eun-Sun Yu, Moo-Jin Park, Ho-Jae Lee, Mi-Young Chae
  • Patent number: 8895733
    Abstract: The invention relates to new derivatives of formula (I), wherein the substituents are as defined in the specification; to processes for the preparation of such derivatives; pharmaceutical compositions comprising such derivatives; such derivatives as a medicament; such derivatives for the treatment of chronic pain.
    Type: Grant
    Filed: October 15, 2013
    Date of Patent: November 25, 2014
    Assignee: Novartis AG
    Inventors: Oliver Barker, Jonathan Mark Bentley, Mark G. Bock, Thomas Cain, Praful Chovatia, Jennifer Ruth Dod, Florence Eustache, Laura Gleave, Jonathan Hargrave, Alexander Heifetz, Richard Law, Ali Raoof, David Willows
  • Publication number: 20140343061
    Abstract: The present invention relates to compounds corresponding to formula (I) in which: —R1 represents a substituted phenyl; —R2 represents: —a substituted phenyl; —a heteroaromatic group, the said group being unsubstituted or substituted one or more times; —R3 represents a group Alk; —R4 represents a hydrogen atom or a (C1-C4)alkyl; —R5 represents a hydrogen atom, a (C3-C6)cycloalkyl or a (C1-C4)alkyl-O-Alk; —or alternatively R4 and R5, together with the nitrogen atom to which they are attached, constitute a heterocyclic radical chosen from: azetidin-1-yl, pyrrolidin-1-yl, piperid-1-yl, morpholin-4-yl; —R6 represents a group —COOAlk, a group —CONH2 or a group —NHSO2Alk; —Alk represents a (C1-C4)alkyl, which is unsubstituted or substituted one or more times with a halogen atom; in the form of the base or of an acid-addition salt. Preparation process and diagnostic and therapeutic use.
    Type: Application
    Filed: December 11, 2012
    Publication date: November 20, 2014
    Inventors: Joelle Arnaud, Martine Artiaga, Francis Barth, Laurent Hortala, Serge Martinez, Pascale Roux
  • Publication number: 20140332793
    Abstract: A compound represented by Formula 1. An organic electric element includes a first electrode, a second electrode, and an organic material layer between the first electrode and the second electrode. The organic material layer includes the compound. When the organic electric element includes the compound in an organic material layer, luminous efficiency, stability, and life span can be improved.
    Type: Application
    Filed: December 21, 2012
    Publication date: November 13, 2014
    Inventors: Junghwan Park, Sunhee Lee, Soungyun Mun, Daesung Kim, Hwasoon Jung, Wonsam Kim, Jihun Byun, Bumsung Lee
  • Publication number: 20140336171
    Abstract: The present invention relates to compounds useful as inhibitors of protein kinases, particularly of JAK family kinases. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.
    Type: Application
    Filed: July 24, 2014
    Publication date: November 13, 2014
    Inventors: Luc Farmer, Gabriel Martinez-Botella, Albert Pierce, Francesco Salituro, Jian Wang, Marion W. Wannamaker, Tiansheng Wang
  • Publication number: 20140326987
    Abstract: A compound represented by Formula 1. An organic electric element includes a first electrode, a second electrode, and an organic material layer between the first electrode and the second electrode. The organic material layer includes the compound represented by Formula 1. When the organic electric element includes the compound in the organic material layer, luminous efficiency, stability, and life span can be improved.
    Type: Application
    Filed: November 13, 2012
    Publication date: November 6, 2014
    Inventors: Junghwan Park, Sunhee Lee, Soungyun Mun, Daesung Kim, Hwasoon Jung, Wonsam Kim, Jihun Byun, Bumsung Lee
  • Publication number: 20140329822
    Abstract: The invention relates to a N-piperidin-4-yl derivative having the general Formula I or a pharmaceutically acceptable salt thereof, to pharmaceutical compositions comprising the same and to the use of said N-piperidin-4-yl derivatives for the treatment and prevention of endometriosis, for the treatment and prevention of pre-menopausal and peri-menopausal hormone-dependent breast cancer, for contraception, or for the treatment of uterine fibroids or other menstrual-related disorders.
    Type: Application
    Filed: September 14, 2012
    Publication date: November 6, 2014
    Inventors: Ines Huisman, Marcelis Van Der Stelt, Wouter Wiedenhof, Charles Anthony Graham Baker-Glenn, Wesley Peter Blackaby, Naimisha Trivedi